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Abstract
Dopamine (DA) is a neurotransmitter in the brain, playing a central role in several disease conditions, including
tetrahydrobiopterin (BH4) metabolism disorders and Parkinson’s disease (PD). BH4 metabolism disorders present a variety of
clinical manifestations including motor disturbance via altered DA metabolism, since BH4 is a cofactor for tyrosine
hydroxylase (TH), a rate-limiting enzyme for DA synthesis. Genetically, BH4 metabolism disorders are, in an autosomal reces-
sive pattern, caused by a variant in genes encoding enzymes for BH4 synthesis or recycling, including 6-pyruvoyltetrahydrop-
terin synthase (PTPS) or dihydropteridine reductase (DHPR), respectively. Although BH4 metabolism disorders and its metab-
olisms have been studied, it is unclear how gene variants cause aberrant DA synthesis in patient neurons. Here, we
generated induced pluripotent stem cells (iPSCs) from BH4 metabolism disorder patients with PTPS or DHPR variants, cor-
rected the gene variant in the iPSCs using the CRISPR/Cas9 system, and differentiated the BH4 metabolism disorder patient-
and isogenic control iPSCs into midbrain DA neurons. We found that by the gene correction, the BH4 amount, TH protein level
and extracellular DA level were restored in DA neuronal culture using PTPS deficiency iPSCs. Furthermore, the pharmacologi-
cal correction by BH4 precursor sepiapterin treatment also improved the phenotypes of PTPS deficiency. These results suggest
that patient iPSCs with BH4 metabolism disorders provide an opportunity for screening substances for treating aberrant DA
synthesis-related disorders.
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Introduction
Dopamine (DA), a physiological chemical of the catecholamine
family, is involved in several important aspects of brain func-
tion, including motor control and reward. DA deficiency causes
various disease conditions including one of the major neurode-
generative diseases, Parkinson’s disease (PD). A rate-limiting
enzyme for DA synthesis is tyrosine hydroxylase (TH). Lack of
tetrahydrobiopterin (BH4; a cofactor of TH) dysregulates DA syn-
thesis and causes movement disorders and psychiatric disor-
ders (1).
BH4 is synthesized from guanosine triphosphate (GTP) by a
set of reactions involving three enzymes, GTP cyclohydrolase I
(GTPCH), which is the first and rate-limiting enzyme, 6-pyru-
voyltetrahydropterin synthase (PTPS), and sepiapterin
reductase (SR), and is recycled by two enzymes, pterin-4a-
carbinolamine dehydratase (PCD) and dihydropteridine reduc-
tase (DHPR) (2). Variants in the genes encoding these enzymes
cause BH4 metabolism disorders (PTPS deficiency; OMIM entry
#261640, DHPR deficiency; OMIM entry #261630) (1). Since BH4 is
also a cofactor of phenylalanine hydroxylase (PAH), BH4 metab-
olism disorders are associated with hyperphenylalaninemia
(HPA). Several BH4 metabolism disorder model mice including
PTPS knock-out mice have been created, and they developed ab-
errant DA synthesis (3,4). BH4 administration in these model
mice partially restored reduced DA levels in the brain (3,4). In
human, the therapeutic efficacy of BH4 itself on neurological
symptoms has been limited, although patients with BH4 metab-
olism disorders are also treated with BH4 supplementation for
HPA caused by ineffective PAH in liver (1). Therefore, it is still
unclear how the gene variant causes aberrant DA synthesis in
patient neurons, and what substance could be used to attenuate
its dysregulation.
Recent advances in human induced pluripotent stem cell
(iPSC) technology have provided access to unlimited numbers of
patient neurons (5). This technology has been used to generate
patient neuronal models of PD and recapitulate key features of
the disease (6,7). Furthermore, the generation of genetically
matched isogenic iPSCs using gene-editing techniques provides
ideal control, since it eliminates differences in genetic back-
ground and provides a clear conclusion regarding gene variant-
specific phenotypes (8,9).
Here, we generated BH4 metabolism disorder patient-
derived iPSCs with gene variants in PTPS or DHPR, which are in-
volved in BH4 synthesis or regeneration, and carried out gene
correction of the variant in the iPSCs by one of the gene editing
techniques, the CRISPR/Cas9 system, to obtain genetically
matched non-diseased controls. We differentiated iPSCs into
DA neurons and investigated the DA synthesis dysregulation,
treated by gene correction or BH4 supplementation.
Furthermore, we tested sepiapterin, which is a substrate of the
salvage pathway in BH4 synthesis, as a promising substance.
Results
Generation of BH4 metabolism disorder-derived iPSCs
and gene correction of variant
BH4 metabolism disorder patients present psychomotor retar-
dation and abnormal movements associated with a DA defi-
ciency. The generation of patient-derived iPSCs and gene
correction of the variant together provide an opportunity to ob-
tain mechanistic insights and screening for new therapeutic
compounds using iPSC-derived disease-affected cells (10,11).
To investigate gene variant-specific disease phenotypes in DA
neuronal culture using iPSCs from patients with BH4 metabo-
lism disorders (Fig. 1A), we initially generated iPSCs from
peripheral blood mononuclear cells of PTPS- or DHPR deficiency
patients. Both iPSCs were positively stained for pluri-
potency markers, displayed a normal karyotype (Fig. 1B), and
were able to differentiate into cells of three germ layers in vitro
(Fig. 1C).
Recent progress in human gene editing using the CRISPR/
Cas9 system allows for the gene correction of a disease-causing
variant in iPSCs, and thereby the generation of genetically
matched control cell lines (12,13). Therefore, to correct the caus-
ative gene variant in BH4 metabolism disorder iPSCs, we used
the CRISPR/Cas9 and piggyBac transposase system. The guide
RNA (gRNA) was designed to target sequences in the vicinity of
the c.243G>A variant in the endogenous PTS gene in PTPS defi-
ciency (Fig. 2A) or the c.176C>A variant in the endogenous
QDPR gene in DHPR deficiency (Fig. 2B). Donor vector contained
a PGK promoter-driven Puro-DTK cassette flanked by piggyBac
inverted terminal repeats (ITR) along with the homology arms
with the corrected PTS or QDPR sequence for integration into the
endogenous genomic locus (Fig. 2A and B). The BH4 metabolism
disorder iPSCs were co-electroporated with the gRNA vector, do-
nor vector, and Cas9 vector, followed by puromycin selection.
Puromycin-resistant colonies were selected and confirmed for
cassette integration by PCR amplification (Supplementary
Material, Fig. S1A and C). This selection cassette was excised
using the piggyBac transposase system, which allows seamless
removal of the piggyBac repeats-flanked sequence. Integration-
positive clones were transiently electroporated by a transposase
expression vector, followed by negative selection with 1-(2-de-
oxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU). FIAU-
resistant colonies were screened by PCR amplification
(Supplementary Material, Fig. S1B and D). Correction of the gene
variant and seamless piggyBac excision in the corrected iPSCs
(PTPS deficiency-Corr and DHPR deficiency-Corr) were confirmed
by sequence analyses (Fig. 2C and D). Corrected iPSCs displayed
embryonic stem (ES) cell-like morphology and expressed the plu-
ripotency markers (Fig. 2E and F). Chromosomal analysis re-
vealed a normal karyotype (Fig. 2E and F). All corrected iPSCs
also could differentiate into all three germ layers in vitro
(Supplementary Material, Fig. S2A). PTPS mRNA and protein level
were greatly increased in PTPS deficiency-corrected iPSCs com-
pared to PTPS deficiency iPSCs (Fig. 2G and H). Similarly, DHPR
mRNA and protein level were increased in DHPR deficiency-cor-
rected iPSCs compared to DHPR deficiency iPSCs (Fig. 2I and J).
The c.243G>A variant in PTS gene reduces the PTPS protein level
via reduction of full-length PTPS mRNA by splicing error (14). On
the other hand, the c.176C>A variant in QDPR gene reduces the
DHPR protein level via creation of a premature stop codon by
nonsense variant. Enzyme activity assay showed that PTPS ac-
tivity was increased in PTPS deficiency-corrected iPSCs com-
pared to PTPS deficiency iPSCs (Supplementary Material, Fig.
S2C). On the other hand, DHPR activity in DHPR deficiency iPSCs
and DHPR deficiency-corrected iPSCs was undetectable in colori-
metric assay.
BH4 metabolism disorder iPSC-derived DA neuronal
cultures show decreased TH protein level and
extracellular DA level
To investigate the phenotypes of disease-affected cells, we dif-
ferentiated iPSCs into DA neurons. Differentiation to DA
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neurons was carried out by using dual SMAD inhibition and the
floor plate induction protocol as previously reported (15,16). At
differentiation day 42, this protocol induced strong expression
of NURR1, FOXA2, LMX1A, TH, AADC, indicating establishment
of midbrain DA neurons (Fig. 3A). Meanwhile, OCT4, one of the
genes that regulate the pluripotency of stem cells, was down-
regulated (Fig. 3A). Further, a high-performance liquid chroma-
tography (HPLC) analysis revealed that the differentiated DA
neuronal culture was functional in extracellular DA release





























Figure 1. Generation and characterization of BH4 metabolism disorder iPSCs. (A) Schematic of strategy for comparing DA neuronal culture using iPSCs from BH4 metab-
olism disorder patients with that using genetically corrected iPSCs. (B) Phase-contrast images, immunocytochemistry for pluripotency markers NANOG and SSEA4,
and karyotype analysis in PTPS deficiency iPSCs and DHPR deficiency iPSCs. Scale bars: 100 lm. (C) In vitro differentiation of PTPS deficiency iPSCs and DHPR deficiency
iPSCs to three germ layers: bIII-tubulin (ectoderm), aSMA (mesoderm), and SOX17 (endoderm). Scale bars: 100lm.
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PTPS deficiency is the most frequent form (60%) of BH4 me-
tabolism disorders (1). Based on the above protocol, we differen-
tiated PTPS deficiency iPSCs and PTPS deficiency-corrected
iPSCs into DA neurons. Although the percentage of bIII-tubulin-
positive neurons in total cells was not significantly different
among DA neuronal cultures, the percentage of TH-positive
neurons among bIII-tubulin-positive neurons was slightly re-
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Figure 2. Gene correction of variant in BH4 metabolism disorder iPSCs. (A,B) Schematic of strategy used for CRISPR/Cas9-mediated gene correction of PTS c.243G>A var-
iant (A) and QDPR c.176C>A variant (B). Red triangle denotes the gene variant. Grey triangle denotes the corrected gene variant. (C,D) Sequencing of genomic PTS locus
in indicated PTPS iPSCs (C) and genomic QDPR locus in indicated DHPR iPSCs (D). The corrected gene variant is marked with an arrow. (E,F) Phase-contrast images, im-
munocytochemistry for pluripotency markers NANOG and SSEA4, and karyotype analysis in PTPS deficiency-corrected iPSCs (E) and DHPR deficiency-corrected iPSCs
(F). Scale bars: 100 lm. (G,I) Gene expression analysis of PTPS deficiency iPSCs and PTPS deficiency-corrected iPSCs for PTPS mRNA (G) and DHPR deficiency iPSCs and
DHPR deficiency-corrected iPSCs for DHPR mRNA (I). GAPDH was used as normalizer. Data represent mean 6 S.D. of n¼ 3. *P< 0.05, **P< 0.01, one-way ANOVA with
Dunnett’s tests compared to patient iPSCs. (H,J) Western blot analysis of PTPS deficiency iPSCs and PTPS deficiency-corrected iPSCs for PTPS and b-actin protein levels
(H) and DHPR deficiency iPSCs and DHPR deficiency-corrected iPSCs for DHPR and b-actin protein levels (J). Asterisk indicates non-specific band.
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compared to that using PTPS deficiency-corrected iPSCs (Fig. 3B–
D). In addition, the area of TH-positive neurons and the TH pro-
tein level were greatly reduced in DA neuronal culture using
PTPS deficiency iPSCs compared to that using PTPS deficiency-
corrected iPSCs (Fig. 3B,E and F), and the extracellular DA level
was also reduced in DA neuronal culture using PTPS deficiency
iPSCs (Fig. 3G). We also determined the metabolic profile of pter-
ins including BH4 and neopterin by HPLC in iPSC-derived DA
neuronal culture. In DA neuronal culture using PTPS deficiency
iPSCs, the BH4 amount was reduced (Fig. 3H) and the neopterin
level was increased (Fig. 3I). These results showed that
c.243G>A variant in PTS gene causes reductions in the BH4
amount, TH protein level and extracellular DA level in DA neuro-
nal culture (Fig. 3J). The observed abnormal phenotypes in DA
neuronal culture using PTPS deficiency iPSCs are consistent with
the symptoms of motor disturbance and reduced homovanillic
acid (HVA), one of the catecholamine metabolites in cerebrospi-
nal fluid (CSF), which are found in patients with PTPS deficiency.
Next, we differentiated DHPR deficiency iPSCs and DHPR
deficiency-corrected iPSCs into DA neurons in the same way. The
TH protein level was slightly reduced in DA neuronal culture using
DHPR deficiency iPSCs (Supplementary Material, Fig. S3A), and the
extracellular DA level was significantly reduced in DA neuronal
culture using DHPR deficiency iPSCs (Supplementary Material, Fig.
S3B). Pterin analysis showed that, unlike the results of DA neuro-
nal cultures using PTPS deficiency iPSCs and PTPS deficiency-
corrected iPSCs, there were no differences in the amounts of BH4
and neopterin between DA neuronal cultures using DHPR defi-
ciency iPSCs and DHPR deficiency-corrected iPSCs (Supplementary
Material, Fig. S3C and D). Further analysis showed a large increase
of total biopterin caused by increases of dihydrobiopterin (BH2)
and biopterin in DA neuronal culture using DHPR deficiency iPSCs
(Supplementary Material, Fig. S3E). The observed reduced DA level
and increased total biopterin in DA neuronal culture using DHPR
deficiency iPSCs are also consistent with profiles of HVA and pter-
ins in patients’ CSF with DHPR deficiency (17).
Sepiapterin improves the TH protein level and
extracellular DA level in PTPS deficiency iPSC-derived
DA neuronal culture
Administration of BH4 is beneficial in PTPS knock-out mice with
aberrant DA synthesis (3). To evaluate whether BH4 treatment can
attenuate the disease phenotypes in human DA neuronal culture
with PTPS deficiency, we treated it with BH4 for five days following
the differentiation period. We also tested sepiapterin, a substrate
of the salvage pathway of BH4 synthesis, in the same manner.
Although the chemical structures of both substrates are very simi-
lar, sepiapterin can more effectively raise the tissue BH4 amount
than BH4 itself (18). Immunocytochemistry revealed that the in-
tensity of the TH staining signal in PTPS deficiency iPSC-derived
DA neuronal culture treated with BH4 or sepiapterin was signifi-
cantly increased compared to non-treatment control (Fig. 4A).
Although the percentages of bIII-tubulin-positive neurons and TH-
positive neurons were not significantly different regardless of the
treatment, increased TH-stained area and TH protein level with
significant neurite localization of TH was observed in BH4- or
sepiapterin-treated DA neuronal culture (Fig. 4A–E). In addition,
the extracellular DA levels in PTPS deficiency iPSC-derived DA
neuronal culture treated with BH4 or sepiapterin were signifi-
cantly higher than that of non-treatment control (Fig. 4F). We
found that sepiapterin increased the extracellular DA level to a
greater extent than BH4 at the same concentration (Fig. 4F).
Traditional treatment of DA-related neurological symptoms
in BH4 metabolism disorders is L-DOPA therapy. Sepiapterin
showed an additive effect with L-DOPA in extracellular DA re-
lease assay, rather than in the TH protein level (Supplementary
Material, Fig. S4A and B). Furthermore, we found that sepiap-
terin treatment also increased the intensity of the TH staining
signal and the extracellular DA level in PD iPSC-derived DA neu-
ronal culture (Supplementary Material, Fig. S4C and D).
Discussion
In the present study, we investigated the patient- and gene
variant-specific DA synthesis dysregulation treated by gene cor-
rection or BH4 supplementation, and evaluated the efficacy of
sepiapterin in human DA neuronal culture with PTPS defi-
ciency. We initially generated iPSCs from BH4 metabolism dis-
order patients with PTPS or DHPR variants. The c.243G>A
variant in PTS gene and the c.176C>A variant in QDPR gene
were corrected using the CRISPR/Cas9 and piggyBac transposase
system. PTPS full-length mRNA and protein level were greatly
decreased in PTPS deficiency iPSCs compared to PTPS deficiency
corrected iPSCs. The c.243G>A variant in PTS gene affects the
splice donor site of exon4 and causes exon4 skipping, leading to
a decreased level of full length mRNA (14). We also confirmed a
splicing variant of PTPS only in patient iPSCs. On PCR amplifica-
tion of PTPS cDNA, PTPS deficiency iPSCs exhibited a shorter
band than the expected wild-type band (452bp) (Supplementary
Material, Fig. S2B). This result suggests that the reduction of
PTPS full-length mRNA caused by splicing error leads to a reduc-
tion of the PTPS protein level in PTPS deficiency iPSCs with c.
243G>A variant. On the other hand, the c.176C>A variant in
QDPR gene is a nonsense variant, resulting in a reduced DHPR
protein level. The nonsense-mediated mRNA decay may cause
a decreased level of DHPR mRNA in DHPR deficiency iPSCs. We
also showed that PTPS activity in PTPS deficiency iPSCs was
lower than that in PTPS deficiency-corrected iPSCs. Although
DHPR activity in DHPR deficiency iPSCs and DHPR deficiency-
corrected iPSCs was undetectable, an increase of oxidized bio-
pterins in DA neuronal culture using DHPR deficiency iPSCs sug-
gests that DHPR activity in DHPR deficiency cells was lower than
that in DHPR deficiency-corrected cells, because low DHPR ac-
tivity causes inefficient reduction of quinonoid dihydrobiopterin
(qBH2) to BH4, resulting in increases of BH2 and biopterin.
DA neuronal culture using PTPS deficiency iPSCs showed de-
creases in TH protein level, extracellular DA level and BH4
amount compared to that using PTPS deficiency-corrected
iPSCs. Reduced CSF biopterin and HVA in patients with PTPS de-
ficiency, have been reported (1). A reduction in the TH protein
level in the striatum has also been reported in autopsy studies
of patients with Dopa-responsive dystonia (DRD), which is
caused by an autosomal-dominant defect in the GCH1 gene
encoding the rate-limiting enzyme for BH4 synthesis (19,20).
Therefore, this result shows that the human PTPS deficiency
iPSC-derived disease model recapitulates the disease pheno-
types in the patient brain with impairment of BH4 synthesis in-
cluding DRD, and the c.243G>A variant in PTS gene is enough
to cause them. One possible mechanism for the TH protein level
reduction is that BH4 or DA deficiency induces phosphorylation
of TH, which in turn leads to its degradation through an
ubiquitin-proteasome pathway (21). On the other hand, DA
neuronal culture using DHPR deficiency iPSCs did not show a
decrease in BH4 amount compared to that using DHPR
deficiency-corrected iPSCs. This result indicates that BH4
was regenerated via an alternative pathway and/or that the
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Figure 3. PTPS deficiency iPSC-derived DA neuronal culture shows decreased TH protein level and extracellular DA level. (A) Gene expression analysis for key midbrain
DA neuron markers. GAPDH was used as normalizer. The expression level of undifferentiated cells (day 0) was set at 1. (B) DA neuronal cultures using PTPS deficiency
iPSCs and PTPS deficiency-corrected iPSCs were stained for TH, the marker for neuron bIII-tubulin and DAPI. Scale bar: 100 lm. (C–E) Percentage of bIII-tubulin-positive
neurons in total cells (C), percentage of TH-positive neurons in bIII-tubulin-positive neurons (D) and the relative area of TH-positive neurons (E) in DA neuronal cultures
using PTPS deficiency iPSCs and PTPS deficiency-corrected iPSCs. (F) Western blot analysis of DA neuronal cultures using PTPS deficiency iPSCs and PTPS deficiency-
corrected iPSCs for TH, bIII-tubulin and b-actin protein levels. (G) Relative level of high potassium evoked-extracellular DA release in DA neuronal cultures using PTPS
deficiency iPSCs and PTPS deficiency-corrected iPSCs. (H,I) Pterin metabolic profiles of DA neuronal cultures using PTPS deficiency iPSCs and PTPS deficiency-corrected
iPSCs: BH4 (H), Neopterin (I). (J) Metabolic pathway of BH4 and DA synthesis in PTPS deficiency. c.243G>A variant in PTS gene causes reductions of BH4 amount, TH pro-
tein level, and extracellular DA level in DA neuronal culture. Enzymes are indicated by the following abbreviations: GTPCH, GTP cyclohydrolase I; PTPS, 6-pyruvoylte-
trahydropterin synthase; SR, sepiapterin reductase; DHPR, dihydropteridine reductase; TH, tyrosine hydroxylase. Quantification represents mean6S.D. of n¼3.
*P<0.05, **P<0.01, Student’s t test.
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biosynthesis of BH4 was increased in DA neuronal culture using
DHPR deficiency iPSCs. Rather, the total biopterin amounts in-
cluding BH2 were increased. A normal BH4 amount and an ele-
vated BH2 amount in CSF of DHPR deficiency patients have been
reported, consistent with our observation in DA neuronal cul-
ture using DHPR deficiency iPSCs. Although the BH4 amount did
not differ between DA neuronal cultures using DHPR deficiency
iPSCs and DHPR deficiency-corrected iPSCs, since it was re-
ported that BH2 can act as an inhibitor of the aromatic amino
acid hydroxylase (22), accumulated BH2 in DA neuronal culture
using DHPR deficiency iPSCs may lead reduced the DA level via
inhibition of TH (Supplementary Material, Fig. S3F).
Current treatment of BH4 metabolism disorders is based on
supplemental therapy with BH4. However, the amount of BH4
that enters the brain is still not sufficient to sustain appropriate
synthesis of DA in patients, and thus concomitant therapy with
neurotransmitter precursors, i.e., L-DOPA, is necessary to re-
cover an appropriate DA level in the patient brain (1). In fact, the
effect of BH4 itself on a patient DA neuronal culture remains
unclear. Our results showed that aberrant DA synthesis in DA
neuronal culture using iPSCs from a patient with PTPS defi-
ciency was attenuated by BH4 supplementation after the differ-
entiation period. Moreover, sepiapterin, a substrate of the
salvage pathway of BH4 synthesis, also improved these disease
phenotypes. Compared to BH4, sepiapterin is a more stable
form and can efficiently pass through the plasma membrane
via equilibrative nucleoside transporter 2 (ENT2) (23).
We actually observed that BH4 disappeared rapidly in culture
medium (Supplementary Material, Fig. S3G) and that sepiap-
terin increased the extracellular DA level more than BH4, with
both at the same concentration. Since ENT2 is also localized in
the blood-brain barrier (24), sepiapterin may be effective against
aberrant DA synthesis in patient brain. However, since BH4 also
has a DA releasing activity that is not dependent on the biosyn-
thesis of DA (25), there is a possibility that intracellular DA stor-
age has been partially lost before the DA release assay is carried
out. In addition, it has been reported that dihydrofolate reduc-
tase (DHFR) activity, which is required for conversion from
sepiapterin to BH4, is low in the brain (26). On the other hand, it
was also reported that a patient with DHFR deficiency devel-
oped cerebral BH4 deficiency (27). Therefore, the in vivo
efficacy of sepiapterin in the human brain is still unknown.
Clinical studies to evaluate the efficacy of sepiapterin may be
necessary.
As described above, L-DOPA is typically used to increase the
DA level in the treatment of neurological symptoms of BH4 me-
tabolism disorders. The clinical outcome of BH4 metabolism
disorders is frequently worsened by the reduced efficacy of
long-term L-DOPA therapy, such as diurnal symptom fluctua-
tions (28–30). For this reason, we investigated the possibility
that sepiapterin is beneficial as an adjunctive therapy with
L-DOPA. Sepiapterin showed an additive effect with L-DOPA in
an extracellular DA release assay, rather than in the TH protein
level, due to the fact that L-DOPA is also converted to DA in
A
B C D E F
Figure 4. Sepiapterin improves TH protein level and extracellular DA level in PTPS deficiency iPSC-derived DA neuronal culture. (A) PTPS deficiency iPSC-derived DA
neuronal cultures treated with DMSO, 30 lM BH4 or 30 lM sepiapterin were stained for TH, the marker for neuron bIII-tubulin and DAPI. Scale bar: 100lm. (B–D)
Percentage of bIII-tubulin-positive neurons in total cells (B), percentage of TH-positive neurons in bIII-tubulin-positive neurons (C), and relative area of TH-positive
neurons (D) in PTPS deficiency iPSC-derived DA neuronal culture treated with DMSO, 30lM BH4 or 30 lM sepiapterin. (E) Western blot analysis of PTPS deficiency iPSC-
derived DA neuronal culture treated with DMSO, 30lM BH4 or 30 lM sepiapterin for TH, bIII-tubulin and b-actin protein levels. (F) Relative level of high potassium
evoked-extracellular DA release in PTPS deficiency iPSC-derived DA neuronal culture treated with DMSO, 30 lM BH4 or 30lM sepiapterin. Quantification represents
mean6 S.D. of n¼ 3. *P< 0.05, ****P< 0.0001, one-way ANOVA with Dunnett’s tests compared to non-treatment control.
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TH-negative/aromatic l-amino acid decarboxylase (AADC) -posi-
tive cells.
It has been reported that familial PD iPSC-derived DA neu-
rons with glucocerebrosidase (GBA) or Leucine-rich repeat ki-
nase 2 (LRRK2) variant showed a reduced DA level (6,31).
Although it is very limited data, we found that sepiapterin treat-
ment also increased the intensity of the TH staining signal and
the extracellular DA level in PD iPSC-derived DA neuronal cul-
ture. Since a single nucleotide polymorphism (SNP) at the GCH1
gene encoding the rate-limiting enzyme for BH4 synthesis was
associated with PD in a large-scale genome-wide association
study (GWAS) meta-analysis (32), sepiapterin treatment might
be more effective in PD with the SNP of GCH1 than without the
SNP of GCH1.
In conclusion, gene correction revealed the effect of gene
variant on BH4 metabolism disorder phenotypes in DA neuronal
culture, and we found that sepiapterin was useful for the treat-
ment of BH4 metabolism disorders with impairment of BH4 syn-
thesis in an in vitro model. The generated patient iPSCs with
BH4 metabolism disorders would provide an opportunity for
screening a substance such as sepiapterin to treat aberrant DA
synthesis-related disorders.
Materials and Methods
Generation of iPSCs and cell culture
Peripheral blood mononuclear cells from a PTPS deficiency pa-
tient with compound heterozygous variant (PTS-c.243G>A/
c.259C>T) and a DHPR deficiency patient with compound het-
erozygous variant (QDPR-c.52G>T/c.176C>A) were reprog-
rammed by inducing the episomal vectors carrying OCT3/4,
SOX2, KLF4, L-MYC, LIN28 and p53 carboxy-terminal dominant-
negative fragment (33) (Supplementary Material, Table S1).
Generated iPSC clones were cultured on iMatrix-511 (Nippi,
Tokyo, Japan)-coated plates with StemFit medium (Ajinomoto,
Tokyo, Japan) supplemented with penicillin/streptomycin.
Gene correction of iPSCs
iPSCs were dissociated using Tryple (Thermo Fisher Scientific,
Waltham, MA), centrifuged, and resuspended in Opti-MEM con-
taining 10 lM ROCK inhibitor, Y27632. iPSCs (1x106 cells) were
electroporated with Cas9, gRNA expression vector, donor vector
(NEPA21, Nepagene, Ichikawa, Japan) and subsequently plated
on iMatrix-511-coated plates with StemFit medium containing
10 lM Y27632. After puromycin treatment, colonies were me-
chanically selected. To screen genomic DNA samples for inte-
gration of the corrective sequences, the target locus was
amplified by PCR. Correctly targeted iPSCs (1x106 cells) were
electroporated with piggyBac transposase expression vector, fol-
lowed by selection with FIAU. Individual colonies were mechan-
ically selected. Deletion of the piggyBac transposon was
analysed by PCR and sequencing.
Karyotyping and genotyping
Karyotyping was performed by the LSI Medience Corporation
(Tokyo, Japan). Genotyping of variants in PTS and QDPR genes
was performed by PCR amplification of genomic DNA and direct
sequencing (3500xL Genetic Analyzer, Thermo Fisher Scientific).
Dopaminergic neuronal differentiation
A feeder-free culture system was used to establish iPSCs.
Dopaminergic neurons were differentiated by quick embryoid
body–like aggregate method and dual SMAD inhibition by modi-
fying previous procedures (15). Briefly, a floating culture of cell
aggregations was introduced, and LDN193189, A83-01, pur-
morphamine, CHIR99021, fibroblast growth factor 8, brain-
derived neurotrophic factor, glial cell-derived neurotrophic fac-
tor, dibutyryl cyclic AMP and ascorbic acid were added.
Dopaminergic neurons were evaluated 6-7 weeks later in vitro.
RNA extraction and quantitative-PCR
Total RNA was extracted using the RNeasy Mini kit (Qiagen,
Hilden, Germany) or SuperPrep Cell Lysis Kit (Toyobo, Osaka,
Japan) according to the manufacturer’s instructions. Samples
were analysed for RNA content using a Nanodrop spectropho-
tometer (Thermo Fisher Scientific). cDNA was synthesized from
1 lg of RNA using the ReverTra Ace (Toyobo). Quantitative PCRs
were carried out with SYBR Premix Ex Taq (Takara, Kusatsu,
Japan) and the StepOnePlus Real Time PCR System (Thermo
Fisher Scientific). The data were assessed using the 2-DDCt
method and normalized by GAPDH expression. Primer se-
quences are described in Supplementary Material, Table S2.
Amplification of PTPS cDNA
The PTPS coding region was amplified with forward primer (5’-
ATGAGCACGGAAGGTGGTG-3’) and reverse primer (5’-
GCTAACCCCAATAGCTATTCTCC-3’) from PTPS deficiency iPSC
cDNA and PTPS deficiency-corrected iPSC cDNA. PCR was car-
ried out with KOD-plus-Neo (Toyobo) and Veriti Thermal Cycler
(Thermo Fisher Scientific).
Western blot analysis
For cell collection, plates were washed with cold PBS, and cells
were lysed on ice in RIPA buffer supplemented with protease in-
hibitor cocktail (Roche, Basel, Switzerland). The lysates were
cleared by centrifugation at 12,000 g for 10 min at 4 C. Protein
concentration was determined by BCA assay (Pierce, Rockford,
IL). About 20–30 mg of protein from the lysate were separated by
10–20% SDS-PAGE and then electrophoretically transferred to a
PVDF membrane (Millipore, Darmastadt, Germany). Membranes
were probed with the following primary antibodies: PTPS
(GeneTex, San Antonio, TX) (110549, 1/1,000), DHPR (homemade
polyclonal, 1/3,000), b-actin (Sigma-Aldrich, St. Louis, MO)
(A5441, 1/5,000), TH (Millipore) (AB152, 1/1,000), bIII-tubulin (Cell
Signaling Technology, Danvers, MA) (5568, 1/1,000). Membranes
were then incubated with secondary peroxidase-conjugated an-
tibody (GE Healthcare, Chicago, IL), and proteins were detected
using ECL Prime Western Blotting Detection Reagent (GE
Healthcare).
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde and blocked with
PBS containing 5% foetal bovine serum. DAPI (40, 6-diamidino-2-
phenylindole) (Thermo Fisher Scientific) was used to label nu-
clei. Fluorescence imaging was performed using IN CELL
Analyzer 6000 (GE Healthcare). The following primary antibod-
ies were used: NANOG (ReproCELL, Yokohama, Japan)
(RCAB0003P, 1/500), SSEA-4 (Millipore) (MAB4304, 1/1,000),
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bIII-tubulin (Millipore) (CBL412, 1/500), SOX-17 (R&D Systems,
Minneapolis, MN) (AF1924, 1/300), aSMA (DAKO, Glostrup
Denmark) (M0851, 1/100) and TH (Millipore) (AB152, 1/500).
Dopamine release assay
iPSC-derived neuronal cells were washed twice with a low KCl
(4.7 mM) solution. The medium was subsequently replaced with
a high KCl solution (60 mM) for 20 min. The solution was col-
lected, and concentration dopamine was determined by HPLC
using a reverse-phase column and an electrochemical detector
system (HTEC-500; Eicom, Kyoto, Japan).
Measurement of pterins
iPSC-derived neuronal cells were lysed on ice in lysis buffer (0.4
M perchloric acid, 0.1 mM EDTA, 1 mM ascorbic acid). The cell ly-
sate was deproteinized by centrifugation at 20,000 g for 10 min.
Culture medium was deproteinized by the addition of 0.4 M per-
chloric acid, 1 mM EDTA, 10 mM ascorbic acid and following
centrifugation. Pterin levels in the obtained supernatant were
measured by HPLC with post-column oxidation and fluores-
cence detector system (34).
Measurement of PTPS activity
PTPS activity was measured as previously described, with minor
modifications (35). The cell lysate (20-40 lg protein) was incu-
bated with 40 lM 7,8-dihydroneopterin triphosphate, 8 mM
MgCl2 and 1 mM dithiothreitol for 1 h at 37C in the dark. The re-
sultant 6-pyruvoyltetrahydropterin (PTP) was converted to
pterin by iodine oxidation, and detected by the fluorometric
HPLC method as described above.
Statistical analysis
The data were analysed by Student’s t test, one-way ANOVA,
followed by Dunnett’s multiple comparison test, or Tukey’s post
hoc test using SAS 9.2.
Supplementary Material
Supplementary Material is available at HMG online.
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